Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.41 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | MARK3 | P27448 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.41 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.41 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.41 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.41 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL807159 | 0.89 | ABL1 (0.38) | SCN5ASCN1ASCN4AKCNH2SCN9A | |
| SCHEMBL14552566 | 0.82 | ASIC3 (0.47) | CA12CA9S1PR1S1PR3CD274 | |
| SCHEMBL27928333 | 0.78 | ASIC3 (0.58) | JAK2PRKD3MARK3PRKCIPRKCD | |
| SCHEMBL17955854 | 0.78 | ASIC3 (0.51) | JAK2PRKD3MARK3PRKCIPRKCD | |
| Hydrochloric Acid SCHEMBL3281306 | 0.77 | CD274 (0.43) | KCNH2S1PR1S1PR3CD274ASIC3 | |
| SCHEMBL21780485 | 0.75 | CA12 (0.41) | CA12CA9SCN5ASCN1ASCN4A | |
| SCHEMBL22563247 | 0.75 | CA12 (0.41) | CA12CA9SCN5ASCN1ASCN4A | |
| SCHEMBL29805916 | 0.74 | FABP6 (0.56) | CA12CA9SCN5ASCN1ASCN4A | |
| SCHEMBL14480649 | 0.74 | FABP6 (0.56) | CA12CA9SCN5ASCN1ASCN4A | |
| SCHEMBL2111130 | 0.74 | SCN5A (0.41) | SCN5ASCN10ANISCHNOTUMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3101013-B1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-3088395-B1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3085694-B1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3098218-B1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3085696-B1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-03-04 | — | — | EP | disclosed |
| US-9676760-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9598435-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| EP-3101013-A1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20160347744-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-12-01 | — | — | US | disclosed |
| EP-3098218-A1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| EP-3085694-A1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160096846-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-04-07 | — | — | US | disclosed |
| US-9193694-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20140135317-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| EP-2726466-A1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8697863-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-8586732-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130184255-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2013006485-A1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| US-20130012492-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184255-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNJ4 | CA12 3939/4885CA9 1989/4885SCN5A 47/4885 |
| US-20130012492-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNJ4 | CA12 3939/4885CA9 1989/4885SCN5A 47/4885 |
| US-20160347744-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNJ4 | CA12 3939/4885CA9 1989/4885SCN5A 47/4885 |
| US-20140135317-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNJ4 | CA12 3939/4885CA9 1989/4885SCN5A 47/4885 |
| US-20160096846-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNJ4 | CA12 3939/4885CA9 1989/4885SCN5A 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.